Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Inhalers Market: By Devices, By Type, By Application, By End User, and Geography
Inhalers Market: By Devices, By Type, By Application, By End User, and Geography
Inhalers market size was valued at US$ 19,445.4 million in 2022 and is poised to grow at a significant CAGR of 4.3% over 2023-2029. Due to an increase in occurrences of respiratory disorders, particularly the diagnosis and treatment of COVID-19, hospital and clinical visits increased considerably, resulting in an increase in demand for inhalers and nebulizers, propelling the market forward. Various collaborations, partnerships, and acquisitions between pharmaceutical companies and smart inhaler manufacturers have increased competition in the smart inhaler industry, and the rise in healthcare expenditure in such economies presents lucrative opportunities for the market; thus, is a great opportunity for key players to invest.
Although inhalers have proven to be very successful devices, the wide variety of devices available can make it difficult for physicians to determine which one is best for a certain patient. In the future years, the market will be driven by the rise in popularity of smart respiratory inhaler devices. Smart inhaler devices connect to a smartphone app, allowing users to keep track of dose reminders and prescription schedules.
Study Period
2024-2030Base Year
2023CAGR
4.3%Largest Market
North AmericaFastest Growing Market
Europe
The rising prevalence of COPD and asthma is a primary driver of market expansion. The number of people aged 65 and above in the United States is expected to nearly treble by 2050, with those aged 85 and up constituting the fastest-growing age group. Patients with asthma and COPD who live longer have more physical and cognitive co-morbidities, which impact their ability to use inhaler devices.
As the amount of ozone and particle matter in the air rises, the likelihood of developing asthma symptoms rises at an alarming rate. As a result, an increase in air pollution is predicted to directly contribute to a spike in asthma and COPD cases, propelling the market forward. However, high cost of the products is impelling the market growth.
The inhaler market in North America is likely to hold a highest revenue share of 39% in 2021 and in the following years, it is predicted to increase at a rapid rate. Better healthcare infrastructure and facilities, a rise in the number of patients suffering from asthma and COPD, acceptance of technologically sophisticated therapies, the presence of major companies, and an increase in healthcare expenditure in the region are all contributing to the region's growth. Furthermore, due to its large senior population, rising disposable incomes, increased healthcare spending, and different developmental activities, Asia-Pacific is expected to be the fastest developing area. Furthermore, in the Asia-Pacific market, India and China are predicted to rise at a fast rate.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2022 |
US$ 19,445.4 million |
|
Market CAGR |
4.3% |
|
By Device Type |
|
|
By Type |
|
|
By Application |
|
Download Free Sample Report
The inhalers market is projected to expand at a CAGR of 4.3% during the forecast period.
Europe is the fastest-growing region for inhalers market
3M Company, Aradigm Corporation, AstraZeneca Plc., Boehringer Ingelheim GmbH, Cipla Inc., GlaxoSmithKline
| 1.Executive Summary |
| 2.Global Inhalers Market Introduction |
| 2.1.Global Inhalers Market - Taxonomy |
| 2.2.Global Inhalers Market - Definitions |
| 2.2.1. By Machinery Type |
| 2.2.2. By Type |
| 2.2.3. By Application |
| 2.2.4. By Region |
| 3.Global Inhalers Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Inhalers Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Inhalers Market By Machinery Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Metered Dose Inhaler |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Dry Powder Inhaler |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Nebulizer |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Inhalers Market By Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Preventive Inhaler |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Reliever Inhaler |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Long-acting Bronchodilators Inhaler |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Inhalers Market By Application, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Asthma |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Chronic Obstructive Pulmonary Disease |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Pulmonary Arterial Hypertension |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Cystic Fibrosis |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Inhalers Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Inhalers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Machinery Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Metered Dose Inhaler |
| 9.1.2.Dry Powder Inhaler |
| 9.1.3.Nebulizer |
| 9.2. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Preventive Inhaler |
| 9.2.2.Reliever Inhaler |
| 9.2.3.Long-acting Bronchodilators Inhaler |
| 9.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Asthma |
| 9.3.2.Chronic Obstructive Pulmonary Disease |
| 9.3.3.Pulmonary Arterial Hypertension |
| 9.3.4.Cystic Fibrosis |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Inhalers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Machinery Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Metered Dose Inhaler |
| 10.1.2.Dry Powder Inhaler |
| 10.1.3.Nebulizer |
| 10.2. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Preventive Inhaler |
| 10.2.2.Reliever Inhaler |
| 10.2.3.Long-acting Bronchodilators Inhaler |
| 10.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Asthma |
| 10.3.2.Chronic Obstructive Pulmonary Disease |
| 10.3.3.Pulmonary Arterial Hypertension |
| 10.3.4.Cystic Fibrosis |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Inhalers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Machinery Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Metered Dose Inhaler |
| 11.1.2.Dry Powder Inhaler |
| 11.1.3.Nebulizer |
| 11.2. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Preventive Inhaler |
| 11.2.2.Reliever Inhaler |
| 11.2.3.Long-acting Bronchodilators Inhaler |
| 11.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Asthma |
| 11.3.2.Chronic Obstructive Pulmonary Disease |
| 11.3.3.Pulmonary Arterial Hypertension |
| 11.3.4.Cystic Fibrosis |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Inhalers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Machinery Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Metered Dose Inhaler |
| 12.1.2.Dry Powder Inhaler |
| 12.1.3.Nebulizer |
| 12.2. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Preventive Inhaler |
| 12.2.2.Reliever Inhaler |
| 12.2.3.Long-acting Bronchodilators Inhaler |
| 12.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Asthma |
| 12.3.2.Chronic Obstructive Pulmonary Disease |
| 12.3.3.Pulmonary Arterial Hypertension |
| 12.3.4.Cystic Fibrosis |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Inhalers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Machinery Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Metered Dose Inhaler |
| 13.1.2.Dry Powder Inhaler |
| 13.1.3.Nebulizer |
| 13.2. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Preventive Inhaler |
| 13.2.2.Reliever Inhaler |
| 13.2.3.Long-acting Bronchodilators Inhaler |
| 13.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Asthma |
| 13.3.2.Chronic Obstructive Pulmonary Disease |
| 13.3.3.Pulmonary Arterial Hypertension |
| 13.3.4.Cystic Fibrosis |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.3M Company (USA) |
| 14.2.2.Aradigm Corporation (California) |
| 14.2.3.AstraZeneca Plc. (UK) |
| 14.2.4.Boehringer Ingelheim GmbH (Germany) |
| 14.2.5.Cipla Inc. (India) |
| 14.2.6.GlaxoSmithKline (UK) |
| 14.2.7.BESPAK (UK) |
| 14.2.8.Beximo Pharmaceuticals Limited (Bangladesh) |
| 14.2.9.Spyryx Biosciences, Inc. (North Carolina) |
| 14.2.10.MidasCare Pharmaceuticals Pvt. Ltd. (India) |
| 14.2.11.Omega Life Sciences Ltd. (Isreal) |
| 14.2.12.Drive DeVilbiss Healthcare Ltd. (UK) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.